Today, the U.S. Food and Drug Administration approved Olumiant (baricitinib) oral tablets to treat adult patients with severe alopecia areata, a disorder that often appears as patchy baldness and affects more than 300,000 people in the U.S. each year. Today’s action marks the first FDA approval of a systemic treatment (i.e. treats the entire body rather than a specific location) for alopecia areata.
FDA approves first systemic treatment for alopecia areata
June 13, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022